A decade of turning mRNA into medicine.
Wren’s scientific work on liquid biopsy began in 2004; the laboratory was established in Branford, Connecticut, in 2014.
Milestones, newest first.
Precision oncology through mRNA liquid biopsy.
The power of mRNA
Positioned between DNA and proteins, mRNA in whole blood gives a real-time picture of tumor activity. Our novel preservative ensures stable, reliable testing.
Our mission
Innovative machine learning, liquid biopsy-RNA in vitro diagnostics for detecting minimal residual disease and predicting cancer prognosis and response to therapeutics.
For decades, cancer management relied on imaging, invasive tissue biopsies and delayed recognition of residual or recurrent disease. Recognizing the need for more sensitive, dynamic molecular monitoring, Wren’s scientific efforts began exploring liquid biopsy technologies in 2004 to detect cancer-associated genetic activity through circulating biomarkers in blood and other non-invasive specimens.
Today, Wren focuses on advanced mRNA-based molecular diagnostics and machine-learning-enhanced bioinformatics supporting earlier cancer detection, molecular surveillance, treatment monitoring and precision oncology. By analyzing tumor-associated genetic signatures from blood and saliva, Wren aims to improve detection of minimal residual disease, recurrence risk assessment and real-time disease monitoring.
Wren’s growing portfolio targets prostate cancer, neuroendocrine tumors, colorectal, pancreatic and lung cancer, melanoma and hematologic malignancies. Through a simple blood or saliva sample, Wren is helping make mRNA liquid biopsy a practical clinical reality.
Providers, order your test here
Order NETest 2.0® or PROSTest® through our portal or with the requisition form — kits ship directly to your office.